Core Perspective - The company has announced the signing of a definitive agreement for the sale of Bozzetto, indicating a strategic move to optimize its portfolio and focus on core operations [2]. Transaction Overview - The transaction is positioned as a significant step for the company, with plans to review upcoming timelines and the intended use of proceeds from the sale [2]. - The call includes participation from key executives, highlighting the importance of the transaction to the company's leadership [3]. Communication and Information - A presentation will be utilized during the call, and it is available on the company's Investor Relations website for stakeholders [3]. - The company acknowledges that some statements made during the call may be forward-looking, which could lead to future results differing from current discussions [3][4].

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [3] Upcoming Event - AIM will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Thomas K. Equels, the CEO of AIM, will provide a corporate overview and business outlook, with a focus on the company's strategic emphasis on pancreatic cancer [1] - The presentation is scheduled for February 11, 2026, at 1:40 PM EST [1]

Core Insights - AIM ImmunoTech Inc. reported positive data from the ongoing Phase 2 clinical study of Ampligen combined with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, showing median survival of 19.7 months compared to 8.6 months with standard care [1][2] - The study aims to assess the clinical benefit rate, overall survival, progression-free survival, immune monitoring, and quality of life for patients [2][3] Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial expected to enroll up to 25 subjects, with 18 patients already enrolled [3] - The study has shown promising results in progression-free survival and overall survival, with no significant toxicity reported, indicating a favorable safety profile [3][4] - The combination therapy appears to enhance the body's immune response, suggesting a coordinated activation of both innate and adaptive immune systems [5] Group 2: Market Potential and Intellectual Property - AIM holds a U.S. patent for Ampligen as an oncology treatment in combination with anti-PD-L1 therapies, extending protection until August 9, 2039 [7] - The company has received orphan drug designations in pancreatic cancer from both the U.S. and EU, providing market exclusivity post-commercial approval [7][8] - AIM believes that advancing Ampligen to Phase 3 clinical trials could present significant financial opportunities for the company and its shareholders [5][8]

Core Insights - AI-Media, a global leader in AI-driven captioning and language solutions, will showcase its real-time translation, caption generation, and audio description technologies at ISE 2026, highlighting their importance in professional audiovisual environments [1][2]. Group 1: Product Offerings - AI-Media will demonstrate LEXI Voice, an AI-driven real-time voice translation solution designed for live events and broadcast environments, enabling seamless multilingual communication without increasing production complexity [1][2]. - In addition to LEXI Voice, AI-Media will present LEXI Text, a real-time AI captioning solution, and LEXI AD, an automatic audio description system aimed at providing accessible audio-visual experiences [2]. - The LEXI suite of solutions is designed to integrate seamlessly with SDI and IP infrastructures, making them suitable for various deployment scenarios, including conferences, corporate communications, live events, sports venues, religious sites, and public facilities [2]. Group 2: Industry Trends - The professional audiovisual industry is rapidly aligning with the operational standards of the broadcasting sector, focusing on high reliability, low latency, and the integration of cross-language and accessibility needs [2]. - AI-Media aims to transform inclusive communication from a value-added service into a fundamental requirement within the industry [2]. Group 3: Engagement and Information - AI-Media looks forward to engaging with industry professionals at ISE 2026 to discuss how language and accessibility technologies can empower live events, broadcasting, and integrated audiovisual environments [3]. - Attendees are invited to visit booth 4L700 to experience AI-Media's real-time voice translation, caption generation, and audio description workflows firsthand [3].

As filed with the Securities and Exchange Commission on January 29, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AIM ImmunoTech Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 52-0845822 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Num ...

Core Insights - AI-Media is showcasing its AI-powered subtitling and language solutions at ISE 2026, emphasizing the importance of real-time translation, captioning, and audio description in professional AV environments [1][2][4] Group 1: Company Overview - AI-Media is a global leader in AI-powered voice translation, captioning, and language orchestration, with a focus on modernizing workflows and enhancing communication [7] - The company offers the LEXI Suite, which includes solutions for real-time voice translation, subtitling, and audio description, aimed at delivering multilingual and accessible experiences [4][7] Group 2: Product Offerings - LEXI Voice is an AI-driven solution that provides real-time voice translation into any language with natural-sounding output and minimal delay, designed for live and broadcast environments [3] - LEXI Text is a real-time AI subtitling solution, while LEXI AD offers automated audio description, collectively supporting inclusive viewing experiences [4] Group 3: Industry Trends - The professional AV industry is moving towards expectations of reliability, low latency, and multilingual accessibility, similar to those in broadcasting [5] - AI-Media's solutions are positioned to help organizations create inclusive experiences from the outset, reflecting a broader industry shift towards inclusive communication as a standard expectation [5][6]

Company Overview - AIM ImmunoTech Inc. is a member of the Medical sector, which includes 931 individual stocks and currently holds a Zacks Sector Rank of 9 [2] - AIM ImmunoTech Inc. belongs to the Medical - Drugs industry, which consists of 141 individual stocks and is currently ranked 96 in the Zacks Industry Rank [5] Performance Analysis - AIM ImmunoTech Inc. has gained about 7.1% year-to-date, which matches the average return of Medical companies [4] - The Zacks Consensus Estimate for AIM's full-year earnings has increased by 3.8% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] - In comparison, Cullinan Therapeutics, another Medical stock, has outperformed the sector with a year-to-date increase of 19.2% [4] Industry Comparison - The Medical - Drugs industry, to which AIM belongs, has seen an average gain of 3.5% this year, indicating that AIM is performing better than its industry peers [5] - Cullinan Therapeutics is part of the Medical - Biomedical and Genetics industry, which has moved up by 22.9% so far this year, and is currently ranked 94 [6]

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise gross proceeds of $12 million for corporate purposes, including clinical trial expenses and debt repayment [1][4]. Rights Offering Details - The subscription rights are non-transferable and can be exercised from February 11, 2026, to February 27, 2026, unless extended [2][5]. - The rights offering includes an over-subscription privilege allowing holders to purchase additional unsubscribed shares, subject to pro-rata allocation if demand exceeds supply [2]. - AIM's leadership, including CEO Thomas K. Equels, has indicated a non-binding intention to participate in the rights offering [3]. Financial Use of Proceeds - The net proceeds from the rights offering will be allocated for general corporate purposes, specifically for clinical trial and manufacturing expenses related to Phase 2/3 pancreatic cancer trials, as well as repaying existing debt [4]. Important Dates - Key dates for the rights offering include: - February 9, 2026: Ownership Day for stockholder record [8] - February 10, 2026: Record Date [8] - February 11, 2026: Subscription Period Begins [8] - February 27, 2026: Subscription Period Ends [8] Registration and Compliance - A registration statement has been filed with the SEC but is not yet effective, meaning securities cannot be sold until it becomes effective [9]. - The rights offering will be conducted only through a written prospectus [9]. Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with its lead product being Ampligen® [11].

Core Viewpoint - AIM ImmunoTech Inc. is conducting a proposed rights offering to raise gross proceeds of $12 million, which will be used for general corporate purposes, including clinical trial expenses and debt repayment [1][5]. Rights Offering Details - The rights offering will provide one non-transferable subscription right for each share of common stock and certain options and warrants held as of the record date of February 4, 2026 [2]. - Each subscription right allows the purchase of one unit at a subscription price of $1,000, with each unit consisting of one share of Series G Convertible Preferred Stock and warrants to purchase 1,492 shares of common stock [2]. - The subscription rights are non-transferable and can be exercised from February 5, 2026, to February 23, 2026, unless extended by the company [3][6]. Leadership Participation - Certain members of AIM's leadership, including CEO Thomas K. Equels, have indicated a non-binding intention to participate in the rights offering [4]. Use of Proceeds - The net proceeds from the rights offering will be allocated for clinical trial expenses related to Phase 2/3 pancreatic cancer trials and to repay certain existing debt obligations [5]. Important Dates - Key dates for the rights offering include: - February 3, 2026: Ownership Day for stockholders of record - February 4, 2026: Record Date - February 5, 2026: Subscription Period Begins - February 23, 2026: Subscription Period Ends [7]. Information Distribution - Broadridge Corporate Issuer Solutions, LLC will mail rights certificates and a prospectus to holders of record starting on or about February 5, 2026 [8].

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 AIM ImmunoTech Inc. (I.R.S. Employer Identification Number) 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Oc ...